-Member Login

Forgot your USERNAME OR PASSWORD?

Job Postings

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Flicker

Journal Highlights

DMD Highlight: Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product–Drug Interaction

Posted on 8/18/2015 4:24:27 PM

fig 1 GuffordMilk thistle is a top-selling herbal product commonly taken for hepatoprotective and chemopreventive purposes. Raloxifene is a cancer chemopreventive drug that undergoes extensive first-pass metabolism via glucuronidation in the intestines. Here, Gufford et al demonstrate that the milk thistle flavolignans silybin A and silybin B are potent inhibitors of raloxifene glucuronidation by UGT1A1, UGT1A8, and UGT1A10, isoforms highly expressed in the intestine. A mechanistic static model predicted a clinical interaction between milk thistle and raloxifene that was considered to be of moderate to high risk, meriting further evaluation. See article by Gufford et al. at Drug Metab Dispos, August 2015, 43:1353-1359, doi:10.1124/dmd.115.065086

Comments (0)


Leave a comment


Blog comments are moderated and will be posted once approved.

Name


Comment:


Enter the code shown below:

Recent Posts

Archive

.

Hot Links 

EB2017 

Join ASPET 

What is Pharmacology? Video 

PharmTalk Blog